[1]
American College of Obstetricians and Gynecologists. ACOG Practice Bulletin. Management of adnexal masses. Obstet Gynecol 2007; 110: 201-4.
[3]
Sölétormos G, Duffy MJ, Othman Abu Hassan S, et al. Clinical use of cancer biomarkers in epithelial ovarian cancer: Updated Guidelines From the European Group on Tumor Markers. Int J Gynecol Cancer 2016; 26: 43-51.
[4]
Zapardiel I, Gorostidi M, Ravaggi A, Allende MT, Silveira M, Macuks R. Utility of human epididymis protein 4 serum marker for the detection of adnexal malignancy: A multicentric prospective study. Eur J Cancer Prev 2016; 26(4): 346-50.
[5]
Granato T, Porpora MG, Longo F, Angeloni A, Manganaro L, Anastasi E. HE4 in the differential diagnosis of ovarian masses. Clin Chim Acta 2015; 446: 147-55.
[6]
American Institute of Ultrasound in Medicine. AIUM Practice Parameter for the performance of ultrasound of the female pelvis. Laurel (MD): AIUM;
2014. Available from:. http://www.aium.org/resources/guidelines/female Pelvis.pdf (Accessed on: October, 15 2018).
[7]
Grab D, Flock F, Stohr I, et al. Classification of asymptomatic adnexal masses by ultrasound, magnetic resonance imaging, and positron emission tomography. Gynecol Oncol 2000; 77: 454-9.
Article Metrics
12
5